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 NICE has accredited the process used by the British Association of 
Dermatologists to produce clinical guidelines. The renewed accreditation is 
valid until 31 May 2021 and applies to guidance produced using the process 
described in Updated guidance for writing a British Association of 
Dermatologists clinical guidance – the adoption of the GRADE methodology 
2016. The original accreditation term began on 12 May 2010. More information 
on accreditation can be viewed at www.nice.org.uk/accreditation 
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1.0 PURPOSE AND SCOPE 
The overall objective of the guideline is to provide up-to-date, evidence-based 
recommendations for the use of topical photodynamic therapy (PDT). The document aims to: 
 offer an appraisal of all relevant literature up to April 2018, focusing on any key
developments
 address important, practical clinical questions relating to the primary guideline
objective.
 provide guideline recommendations and if appropriate research recommendations
The guideline is presented as a detailed review with highlighted recommendations for practical 
use in primary care and in the clinic, in addition to an updated Patient Information Leaflet (PIL; 
available on the BAD website, www.bad.org.uk/leaflets). 
1.1 Exclusions 
The guideline does not cover systemically administered PDT or PDT as a treatment option for 
genital warts and anal intraepithelial neoplasia as these are out of the remit of Dermatology 
for this guideline 
2.0 METHODOLOGY 
This set of guidelines has been developed using the BAD’s recommended methodology1 with 
reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument 
[www.agreetrust.org]2 and the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE).3 Recommendations were developed for implementation in the UK 
National Health Service (NHS).  
The guideline development group (GDG), which consisted of consultant dermatologists (later 
joined by a trainee dermatologist), a consultant physicist, a photobiology technologist, a 
patient and a technical team (consisting of a guideline research fellow and project manager 
providing methodological and technical support), established several clinical questions 
pertinent to the scope of the guideline and a set of outcome measures of importance to 
patients, ranked according to the GRADE methodology,4 (see section 3.1.1 & 3.2).  
A systematic literature search of PubMed, MEDLINE, EMBASE, Cochrane and AMED 
databases was conducted to identify key articles for PDT from 1st January 2007 up to April 
2018; search terms and strategies are detailed in the supplementary information (Appendix 
L). Additional references relevant to the topic were also isolated from citations in reviewed 
literature and the previous versions of the guidelines. Evidence from included studies was 
graded according to the GRADE system (high, moderate, low or very low quality). 
Recommendations are based on evidence drawn from systematic reviews of the literature 
pertaining to the clinical questions identified; the summary of findings with forest plots 
(Appendix B), GRADE evidence profiles indicating the quality of evidence (Appendix E), tables 
Linking the Evidence To the Recommendations (LETR) (Appendix D), PRISMA flow diagram 
(Appendix I) and list of excluded studies (Appendix J) are detailed in the supplementary 
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information and a separate systematic review for BCC.5 The strength of recommendation is 
expressed by the wording and symbols as shown in Table 1.  
 
Strength Wording Symbols Definition 
Strong 
recommendation for 
the use of an 
intervention 
“Offer”  
(or similar, e.g. 
“Use”, “Provide”, 
“Take”, 
“Investigate”, 
etc.) 
 
Benefits of the intervention outweigh the 
risks; most patients would choose the 
intervention whilst only a small proportion 
would not; for clinicians, most of their 
patients would receive the intervention; 
for policy makers, it would be a useful 
performance indicator. 
Weak 
recommendation for 
the use of an 
intervention 
“Consider”  
Risks and benefits of the intervention are 
finely balanced; most patients would 
choose the intervention but many would 
not; clinicians would need to consider the 
pros and cons for the patient in the 
context of the evidence; for policy 
makers, it would be a poor performance 
indicator where variability in practice is 
expected. 
No recommendation Θ 
Insufficient evidence to support any 
recommendation. 
Strong 
recommendation 
against the use of 
an intervention 
“Do not offer”  
Risks of the intervention outweigh the 
benefits; most patients would not choose 
the intervention whilst only a small 
proportion would; for clinicians, most of 
their patients would not receive the 
intervention. 
Table 1: Strength of recommendation ratings 
 
 
3.0 INTRODUCTION  
 
3.1 Topical photodynamic therapy in non-melanoma skin cancers and precancerous 
lesions 
 
Topical PDT has been approved in over 18 countries worldwide for use in at least one NMSC 
indication.  
 
Currently, three prodrugs are licensed for use in topical PDT, a formulation of 5-
aminolaevulinic acid (ALA), Levulan® (DUSA Pharmaceuticals, Wilmington, MA, U.S.A.) for 
actinic keratosis (AK), and an esterified formulation, methyl aminolaevulinate (MAL), Metvix® 
(PhotoCure ASA, Oslo, Norway and Galderma, Paris, France) for AK, SCC in situ, and 
superficial and nodular basal cell carcinoma (BCC). A nanoemulsion (nc-ALA), Ameluz® 
(Biofrontera AG, Leverkusen, Germany) is licensed for PDT in combination with red light for 
the treatment of mild and moderate AK. The licensed indications are for the treatment of non-
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hyperkeratotic AK, SCC in situ and superficial BCC (and in certain thin, nodular BCC) in adults. 
The nc-ALA (Ameluz®) is also recently licensed for treatment of superficial and/or nodular 
BCC unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor 
cosmetic outcome in adults. 
 
Daylight PDT for AK is a recent indication. Metvix® is licensed for PDT in combination with 
daylight and is being being increasingly used as a light source in the treatment of AK.  
 
3.1.1 Place in the treatment pathway 
 
Topical PDT is used in selected patients after considering the appropriateness, clinical 
efficacy, other modalities of treatment, patient age, lesion site, histology, cosmesis and patient 
choice. 
 
To address these issues the GDG has asked the following question in relation to the use of 
topical PDT in the treatment of non-melanoma skin cancer (NMSC) (See supplementary 
information Appendix A for full review protocol):  
 
Review Question 1: 
In adults with a non-melanoma skin cancer (NMSC)and pre-cancerous lesions,* what are the 
clinical effectiveness/efficacy, safety and tolerability of photodynamic therapy (MAL-PDT, 
ALA-PDT) compared with cryotherapy, curettage, surgical excision, topicals, laser therapy, 
placebo, no treatment, each other or in combination treatment 
 
*Including actinic keratosis (AK), SCC in situ (Bowen’s disease), basal cell carcinoma (BCC) 
(superficial, nodular and other), squamous cell carcinoma (SCC), skin cancer prophylaxis, 
cutaneous T-cell lymphoma (CTCL), intraepithelial neoplasia of the external genitalia (PIN, 
VIN & extragenital), extramammary Paget’s disease, hyperkeratosis in organ transplant 
patients 
 
3.2 Topical photodynamic therapy for infectious and inflammatory dermatoses 
 
Topical PDT has also been used in the treatment of a number of inflammatory conditions on 
an unlicensed basis.  
 
To address these issues the GDG has asked the following question in relation to the use of 
topical PDT in the treatment of inflammatory conditions with the following criteria (case series 
with patient number size ≥4 will be included) (See supplementary information Appendix A for 
full review protocol): 
 
Review Question 2: 
In adults with certain infectious and inflammatory dermatoses,† what are the clinical 
effectiveness/efficacy, safety and tolerability of photodynamic therapy (MAL-PDT, ALA-PDT) 
compared with standard treatment modalities, including topical therapies, systemic therapies, 
UVB phototherapy, control or each other 
 
†Including acne, actinic cheilitis, disseminated superficial actinic porokeratosis, alopecia 
areata, angiofibroma, cutaneous leishmaniasis, Darier’s disease, erythrasma, folliculitis, 
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fungal infections, Granuloma annulare, hypertrophic scars, keratoacanthoma, lichenoid 
dermatoses, molluscum contagiosum, morphoea & localised scleroderma, interdigital 
mycoses, necrobiosis lipoidica, perioral dermatitis, photorejuvenation, porokeratosis, 
psoriasis, radiodermatitis, rosacea, sebaceous hyperplasia, viral warts, vulval lichen 
sclerosus, vulvodynia, wound healing, Zoon’s balanitis. 
 
Outcomes 
 
The GDG also established a set of outcome measures of importance to patients (treatment) 
for each review question, which were agreed by the patient representative, ranked according 
to the GRADE methodology,4 data on which are extracted from included studies (See 
Appendix F). Outcomes ranked 7, 8 and 9 are critical for decision-making; those ranked 4, 5 
and 6 are important but not critical for decision making: 
 
NMSC and pre-cancerous lesions 
Clearance of treated disease* (3 months initial lesion clearance)   (9) 
Sustained clearance of treated disease* (1 year)     (9) 
Sustained clearance of treated disease* (2 years SCC in situ; 5 years BCC) (9) 
Recurrence rate (> 1 year)        (8) 
Severe pain (leading to break in treatment/use of local analgesia)   (8) 
Cosmetic outcome         (6) 
Treatment tolerability – low or manageable pain     (5) 
Other adverse effects – pigmentation, etc.      (4) 
 
Infectious and inflammatory dermatoses  
Improvement of inflammatory/infectious dermatosis† (3 months)   (9) 
Recurrence rate (only for infectious dermatosis) (6 months)   (8) 
Severe pain (leading to break in treatment/use of local analgesia)   (8) 
Cosmetic outcome          (6) 
Treatment tolerability – low or manageable pain     (5) 
Other adverse effects – pigmentation, etc.       (4) 
Treatment associated down-time (photorejuvenation)    (3) 
Quality of Life (QoL) after treatment (acne)      (3) 
 
 
 
4.0 SUMMARY OF RECOMMENDATIONS 
 
The following recommendations and ratings were agreed upon unanimously by the core 
members of the GDG and patient representative. For further information on the wording used 
for recommendations and strength of recommendation ratings see section 2. The evidence for 
recommendations is based on the studies as listed (See Appendices B, C, D, E & F for detail 
and discussion of the evidence). GDG recommendations relating to referral pathways are 
based on discussion and clinical experience, as evidence-based details are not available at 
the time of writing. The GDG is aware of the lack of high-quality evidence for some of these 
recommendations, therefore strong recommendations with an asterisk (*) are based on 
available evidence, as well as consensus and specialist experience. Good practice point 
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(GPP) recommendations are derived from informal consensus. Please note that 
recommendations made in this guideline may only partly overlap with formal licensed 
indications for the use of topical PDT in skin, hair and nail disorders. 
 
The clinical efficacy and appropriateness of other treatment modalities should also be 
considered, taking into account lesion site, histology, cosmesis, patient age and patient 
choice. 
 
All the recommendations listed below apply where service provision makes them practically 
possible to do so. 
 
Preparation prior to PDT 
 
R1 (GPP) Explain the potential benefits and harms of topical PDT therapy to the patient and 
provide a BAD Patient Information Leaflet (PIL; www.bad.org.uk/leaflets) for PDT before 
choosing the treatment  
 
R2 (GPP) Refer to the appropriate summaries of product characteristics (SPCs) on the 
electronic Medicines Compendium (eMC) when administering PDT as there are different 
preparation and administration procedures for each licenced indication 
 
Basal cell carcinoma (BCC) 
 
R3 () Offer* topical PDT as a treatment option to people with superficial BCC, particularly 
for poorly healing or cosmetically sensitive skin sites, multiple lesions and large area lesions 
 
R4 () Consider topical PDT to people with thin (<2mm) nodular BCC in situations where 
other treatments are not practical or contraindicated (see R6) 
 
R5 () Offer a further cycle of PDT to residual lesions where the BCC have shown a good 
response to the preceding treatment 
 
R6 ( ) Do not offer topical PDT as a standard treatment for nodular BCC at high-risk sites 
 
R7 (GPP) Use red light and not that of a shorter wavelength (blue or green light; nor daylight) 
for enhanced penetration for BCC 
 
 
Squamous cell carcinoma in situ (SCC in situ; Bowen’s disease) 
 
R8 () Offer PDT as a treatment option to people with SCC in situ (Bowen’s disease), 
particularly for poorly healing or cosmetically sensitive skin sites, multiple lesions and large 
area lesions 
 
 
Actinic keratosis (AK) 
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R9 () Offer topical PDT as a treatment option to people with AK, particularly for 
cosmetically sensitive skin sites, multiple lesions and large area lesions 
 
R10 () Offer a further cycle of topical PDT to residual lesions where the AK lesions have 
shown a good response to the preceding treatment 
 
R11 () Consider daylight PDT as a treatment option for people with mild (slightly palpable 
AK, more easily felt than seen; Olsen Grade I) or moderate (moderately thick AK, easily felt; 
Olsen Grade II) AK lesions where pain is likely to be an issue, particularly for confluent areas 
on the face or scalp 
 
R12 () Consider combining topical PDT with other treatment modalities if feasible (e.g. 
imiquimod or pre-treatment with ablative fractional laser) for people with thick (very thick or 
obvious AK; Olsen Grade III) AK lesions 
 
Squamous cell carcinoma (SCC) 
 
R13 () Consider PDT as a treatment option for microinvasive SCC if surgery is 
contraindicated 
 
R14 () Do not offer PDT as a treatment option for invasive SCC 
 
Skin cancer prophylaxis 
 
R15 () Consider field-PDT as prophylaxis to reduce the emergence of new lesions in people 
with AKs / NMSC, including those with organ transplantation 
 
Vulval intraepithelial neoplasia (VIN) 
 
R16 () Consider PDT as a treatment option for VIN lesions which are:  
 uni-focal 
 non-pigmented 
 without associated HPV infection 
 and with lower grades of dysplasia 
 
Erythroplasia of Queyrat (EQ) 
 
R17 () Consider PDT as a treatment option for EQ, bearing in mind that pain may be a 
limiting factor 
 
Cutaneous T-cell lymphoma (CTCL) 
 
R18 () Consider PDT as a treatment option for CTCL particularly for early-stage disease, 
few localized lesions and challenging sites such as skin folds 
 
Extramammary Paget's disease (EMPD) 
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R19 () Consider PDT as a treatment option for EMPD for thin or small lesions:  
 where Paget cell infiltrate is less dense  
 or when there is limited adnexal involvement 
 
R20 () Consider PDT as a treatment option for EMPD either before or after surgery 
R21 () Consider CO2 laser prior to PDT as a treatment option for EMPD 
Acne 
 
R22 () Consider PDT as a treatment option for acne where standard treatments are 
ineffective or contraindicated 
 
Antimicrobial – cutaneous leishmaniasis, fungal infections, viral warts 
 
R23 () Consider conventional PDT as a treatment option for cutaneous leishmaniasis, 
particularly in cosmetically sensitive skin sites 
 
R24 () Consider daylight PDT as a treatment option for cutaneous leishmaniasis, bearing 
in mind that many treatments may be required 
 
R25 () Consider PDT as a treatment option for recalcitrant viral warts 
 
R26 () Do not offer* PDT as a treatment option for fungal infections 
 
Psoriasis 
 
R27() Do not offer* PDT as a treatment option for psoriasis 
 
Actinic cheilitis 
 
R28 () Consider PDT as a treatment option for actinic cheilitis 
 
Insufficient evidence to support any recommendation 
 
(Θ) Currently there is insufficient evidence to support any recommendation for the following: 
alopecia areata, angiofibroma, Darier’s disease, folliculitis, granuloma annulare, hypertropic 
scars, keratoacanthoma, lichenoid dermatoses, necrobiosis lipoidica, morphoea & localised 
scleroderma, perioral dermatitis, photorejuvenation, porokeratosis, radiodermatitis, rosacea, 
sebaceous hyperplasia, vulval lichen sclerosus, vulvodynia, wound healing and Zoon’s 
balanitis.   
 
List of key future research recommendations (FRRs) 
 
FRR1 Comparison of topical therapies with PDT for superficial/thin nodular BCC: 
 where there is residual BCC at 3 months after first cycle of PDT 
 to include detailed assessment of post-treatment events and tolerability assessed 
both cumulatively over time and in intensity (including pain, irritation), and patient 
treatment preference  
 
FRR2 Potential for combination therapy including PDT to optimise sustained response rates 
in BCC 
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FRR3 Comparison of PDT in combination with other therapies for large lesions or lesions 
unresponsive to monotherapy in BCC 
 
FRR4 Comparison of conventional versus fractionated PDT in BCC 
 
FRR5 Comparison of efficacy of conventional vs. daylight PDT for AK in an RCT 
 stratified by Olsen Grade of AK lesion, complete response and recurrence rates 
 at sites other than the scalp, treatment of individual AK lesion(s) versus treatment of 
field area 
 
FRR6 Comparison of cost effectiveness of conventional vs. daylight PDT in AK, with 
consideration of complete response and recurrence rates 
 
FRR7 What is the efficacy and safety of daylight PDT in SCC in situ (Bowen’s disease)? 
 
FRR8 Comparison of PDT with curettage + cautery in SCC in situ (Bowen’s disease) 
 
FRR9 Comparison of PDT in combination with other therapies for large lesions or lesions 
unresponsive to monotherapy in SCC in situ (Bowen’s disease) 
 
FRR10 Further study of the efficacy and safety of PDT for superficial microinvasive SCC 
where surgery is contraindicated 
 
FRR11 Potential for combination therapy including PDT to achieve sustained high response 
rates in microinvasive SCC when surgery is contraindicated 
 
FRR12 Need for RCT data to assess the efficacy of PDT for VIN, EQ, AIN, CTCL and 
EMPD. 
 
FRR13 What measures can be used to limit pain in patients with genital lesions treated with 
PDT? 
 
FRR14 Improved modelling of light transmission, photosensitiser distribution and tumour 
shape and location to enable more accurate prediction of outcome 
 
FRR15 Need for larger well-designed randomized, controlled, adequately powered studies of 
full face studies rather than split-face studies for acne, with a longer follow-up required to 
determine period of remission and if sustained. 
 
FRR16 Need for well-designed randomized, controlled, adequately powered studies with a 
longer follow-up and ideally histological confirmation of clinical findings for 
photorejuvenation. 
 
FRR17 Need for larger well-designed randomized, controlled, adequately powered studies 
comparing conventional PDT with topical paromomycin / cryotherapy / placebo for 
cutaneous leishmaniasis 
 
FRR18 Need for larger well-designed randomized, controlled, adequately powered studies 
comparing daylight PDT with topical paromomycin / cryotherapy / placebo for cutaneous 
leishmaniasis 
 
FRR19 Need for well-designed randomized, controlled, adequately powered studies 
comparing PDT with conventional treatments for vitiligo 
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 5.0 PHOTOSENSITIZING AGENTS  
 
PDT is commonly performed using the prodrugs aminolaevulinic acid (ALA) and its methyl 
ester, methyl aminolaevulinic acid (MAL). MAL is demethylated by intracellular esterases, and 
ALA is metabolised by the haem biosynthetic pathway, leading to accumulation of the 
photosensitiser protoporphyrin IX (PpIX). The PpIX has several absorption peaks, with the 
632 nm (red light) peak being utilised most frequently for irradiation, in treatment of a range of 
skin lesions including BCC and BD, whilst the 410 nm (blue light) peak is also utilised for more 
superficial lesions, i.e. AK.  
 
The prodrugs are relatively selectively concentrated in the target lesion. ALA is hydrophilic 
and addition of the methyl group produces the more lipophilic MAL, with the aim to enhance 
tissue penetration.6 Studies comparing ALA and MAL in AK and inflammatory acne report 
higher PpIX levels but less selectivity for the target tissue with ALA, and less pain with MAL-
PDT, although similar treatment efficacy of ALA- and MAL-PDT is seen.6 Both ALA- and MAL-
PDT are effective in BD and BCC, with less pain reported in MAL-PDT.7  
 
PDT with MAL (Metvix®) is performed according to its license, a treatment cycle comprising 1 
PDT treatment in AK, and 2 PDT treatments with a one-week interval in BD and in nodular 
and superficial BCC, and light exposure 3 hours after pro-drug application. A second PDT 
cycle is usually performed at 3 months in incompletely responding lesions. In contrast, a range 
of different ALA formulations and ALA-light exposure intervals have been used. A self-
adhesive ALA patch has been licensed for use in mild AK.8 A gel formulation of ALA with 
nanoemulsion, nc-ALA (BF-200 ALA, Ameluz®) which enhances ALA stability and skin 
penetration, has shown higher complete lesion clearance than MAL-PDT in thin-moderate 
thickness AK.9 The nc-ALA is also recently licensed for the treatment of superficial and nodular 
BCC. 
 
Further approaches to enhance skin target cell delivery of prodrugs/photosensitisers include 
the use of liposomal delivery.10,11 With liposomal ALA, a low (0.5%) ALA concentration reduces 
phototoxic effects in acne.12 Levels of PpIX have been potentiated by adjuvant treatment with 
ferrochelatase inhibitors13 differentiating agents, including low-dose methotrexate and vitamin 
D,14 and heat.15 Higher PpIX levels are also seen with ALA after skin surface disruption, e.g. 
by pretreatment with fractional laser. 16  
 
Attempts have also been made to perform topical PDT using exogenous photosensitisers, 
particularly to pursue the advantage of using chemicals with longer activation wavelength, and 
hence potentially PDT with deeper tissue effect. This includes exploratory studies of the use 
of silicon phthalocyanine (Pc4), peak absorption 675 nm, which was safe and tolerable in a 
dose-escalation study in NMSC and CTCL17 and meso-tetra(hydroxyphenyl)chlorin (mTHPC), 
peak absorption 652 nm.10 A Phase IIa randomised controlled trial of PDT with topical 
application of cationic photosensitizer PPA904 [3,7-bis(N,N-dibutylamino)phenothiazin-5-ium 
bromide] versus placebo in chronic leg ulcers demonstrated significant reduction in bacterial 
load with a trend towards wound healing.18 
 
 
6.0 PHOTODYNAMIC DIAGNOSIS (PDD)  
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 Photodynamic diagnosis (PDD) employs the non-invasive detection plus/minus quantification 
of photosensitiser fluorescence; when performed, this is usually prior to treatment with PDT 
or another modality. Topical prodrugs ALA and MAL have been utilised, with PpIX 
fluorescence used both in therapy and diagnosis.19 
 
The simplest method involves the illumination of a porphyrin-enriched tumour by Wood’s lamp 
(long wavelength ultraviolet-A) revealing a brick-red fluorescence. However, this is a crude 
technique and relevance to clinical practice is undefined. The fluorescence can also be 
quantitatively measured assessed through use of CCD camera systems coupled digital 
imaging.20 
 
In addition to wide field optical imaging, technological approaches include surface point 
measurements (e.g. fluorescence spectroscopy), which allow assessment of superficial 
tissues. Multimodal techniques are in development, combining fluorescence with technologies 
such as ultrasound or optical coherence tomography (OCT) or confocal microscopy, allowing 
greater depth assessment.19  
There is particular interest in applying PDD to delineate lesional margins,21 with human studies 
indicating high predictive value, e.g. in MAL-PDD of BCC.22,23 Assessment of PpIX levels and 
kinetics can also be applied in a range of situations including evaluation of prodrugs, impact 
of adjunctive agents and prediction of clinical clearance.24 In future, PDD could enable tailoring 
of treatment regimens to optimise patient outcomes. 
 
7.0 LIGHT SOURCES AND DOSIMETRY  
 
A light source is required that will deliver the necessary irradiance within the absorption band 
of the photosensitizer at sufficient depth to destroy the target tissue while causing minimal 
damage to surrounding healthy tissue.25,26 The most common light sources used for PDT of 
skin lesions are laser diodes, filtered lamps or light emitting diodes (LEDs). LEDs have the 
advantage of a narrow spectral emission with minimal cost and are virtually maintenance-free. 
These all emit light centred around 630 nm. Fluorescent lamps with an emission spectrum 
between 400 and 450 nm are also used for PDT of AK. There are numerous publications 
describing the use of other light sources including dye lasers and intense pulsed lights (IPLs). 
27-32 In the case of MAL-PDT standard procedures involve the use of LEDs.6,33 (See 
supplementary information: Appendix M for further detail and spectra.) 
 
Only a few clinical comparative studies have been carried out using different light sources. 
Narrow-band LEDs appeared more efficacious than broad-band LEDs in one study34  but other 
studies failed to find a significant difference when different light sources were used.35-37 There 
is evidence to support a fractionated treatment regime in which a dark interval is introduced 
between two light fractions.38,39 Also, pre-treatment using a fractional laser may enhance 
penetration of the pro-drug.16,40,41 
 
Traditionally, PDT has been a hospital-based treatment using relatively bulky light sources. 
Developments are underway to facilitate easier delivery of the treatment. These include so-
called ambulatory PDT using a lightweight portable LED device42,43 and light-diffusing 
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textiles.44  Another novel way to deliver PDT outside the hospital is to use daylight as the light 
source.45-47  
 
Commercial PDT light sources are supplied with no evidence of traceability to national 
measurement standards to validate indicated delivered dose.48 In one case, the dose fell to 
just over a third at a distance of only 2 cm from the central area.  
 
It is important to know what is the effective dose being delivered to the target cells.49,50 Factors 
such as photobleaching can increase the treatment depth and use of Monte Carlo (MC) 
models provide an insight into generation of singlet oxygen within the tumour.26,51-55 MC 
simulations predict a 72% increase in depth of tumour necrosis for a wavelength of 630 nm 
compared to 405 nm.55  MC modelling also showed that the effective treatment depth 
increased from 2.0 mm to 2.7 mm for a light dose of 37.5 J/cm2 and 75 J/cm2, respectively, 
and increased further to 3.3 mm for 150 J/cm2, largely due to photobleaching.53 
 
8.0 PROTOCOLS FOR DELIVERY OF PHOTODYNAMIC THERAPY  
 
A successful PDT outcome requires the optimisation of applying the appropriate 
prodrug/drug/photosensitiser, light parameters and oxygen thereby achieving the mechanism 
of action intended. The resultant photodynamic reaction at the target cell produces the 
therapeutic result. PDT utilises the higher selectivity of the photosensitizer for the target tissue 
compared to healthy tissue. The topically applied photosensitizer prodrugs are converted 
intracellularly to active photosensitizers, principally PpIX. Reactive oxygen species, i.e. singlet 
oxygen produced by the photodynamic reaction, cause programmed cell death, i.e. apoptosis, 
and necrosis of target cells, and can also modify cellular processes via molecular events. In 
addition to direct effects of PDT on lesional tissue, indirect effects can occur both through 
dermal vascular events and via the host inflammatory and immune responses.56 
The various regimes of PDT delivery with multiple different combinations are aimed to optimise 
the therapeutic response. 
The following recommended protocols refer to the two prodrugs that are currently licensed for 
use in the UK: methyl aminolaevulinate (MAL) Metvix® for non-hyperkeratotic AKs, SCC in 
situ and superficial BCCs, and BF-200 ALA (Ameluz®) nc-ALA which is the only ALA approved 
in UK licensed for AKs on face and scalp, recently also licensed for BCC. 
Variation of administration of PDT protocols between studies may contribute to limitations in 
the ability to compare studies.  
Lesion preparation is a routinely performed aspect of delivering topical PDT regardless of 
which product is being used. The gentle removal of crusts and scale with scalpel/curette is 
commonly performed without causing pain and not requiring local anaesthesia. The treatment 
area could be degreased with 70% isopropyl alcohol (especially for Ameluz®). Other 
additional preparation techniques or combination treatment approach reported include 
microneedling, skin vapourization with CO2 laser or ablative fractional resurfacing.57-61  
A layer of prodrug cream approximately 1 mm thick is applied via spatula to the lesion and the 
surrounding 5-10 mm of skin. 
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Treatment sites are covered with light-occlusive dressings as full exposure to ambient light 
during the incubation period potentially increases activation of PpIX superficially (bleaching), 
thereby reducing deeper prodrug/photosensitiser penetration before photoactivation. 
Occlusion is standard practice for conventional PDT using MAL and nc-ALA. 
After the incubation time of 3 hours, the dressing is removed with the remnant cream or gel 
wiped off with 0.9% saline solution. This is followed by illumination using red-light spectrum 
570-670 nm achieving a dose of 75 J/cm2, or narrow spectrum 635 nm LED lamp light with a 
distance from skin to lamp of 5-8 cm achieving a dose of 37 J/cm2 with intensity approximately 
50-80 mW/cm2. 
The regime for AK is one treatment, whereas for BCC and SCC in situ is two treatments 7 
days apart. Protocols used in other indications are discussed with each indication.  
Daylight PDT is performed by the application of an organic sunscreen initially,62 followed by 
lesion preparation 15 minutes later, then MAL to the treatment area without occlusion. After 
30 minutes’ application, patients are exposed to daylight for 1.5-2 hours when treating AK.46,63 
Location, weather and the availability of daylight could be limitations. 
 
9.0 ADVERSE EFFECTS 
 
The most apparent acute adverse effect of topical PDT is pain. Historically, with high irradiance 
regimens, this was a limiting factor for the effective delivery of PDT in some instances. PDT-
induced pain appears to have neurogenic and inflammatory components. Predictive factors 
for PDT-induced pain have been investigated but many studies have multiple confounding 
influences. Overall, it appears that treatment of larger lesions or areas, particularly if there is 
field change photodamage, and those on the head and neck, are associated with the likelihood 
of higher levels of pain than smaller lesions or fields on non-head and neck sites. Methods of 
pain relief such as topical analgesics and anaesthetics, cold air and pausing irradiation have 
little or limited impact on minimising pain experienced, although nerve blockade may be more 
effective. The introduction of PDT with lower irradiance regimens, e.g. daylight PDT, has 
markedly improved both the ability to deliver to a large area and the tolerability of the 
treatment.  Indeed, with current usage and appropriate selection of PDT treatment regimens, 
pain appears no longer to be a major limiting factor for most patients receiving PDT.  
 
The inflammation induced during topical PDT is an expected effect rather than an adverse 
effect, manifesting as erythema, oedema and even frank urticaria in some patients. Hyper- or 
hypo-pigmentation are also uncommon occurrences, which may last for weeks to months after 
treatment. Scarring is a rare event and excellent cosmetic outcome is a considerable 
advantage of PDT in comparison with other treatments such as cryotherapy.  
 
Rarely, contact sensitisation to the prodrugs used in topical PDT may occur and this should 
be considered particularly for patients who have received treatment to large areas and in 
multiple sessions, such as those with extensive field change and actinic keratoses, including 
patients receiving daylight PDT. Vigilance is required with respect to patients developing 
unusually severe reactions or dermatitic responses after PDT; patch testing should be carried 
out if indicated. Other medium-term to chronic adverse effects of PDT are rare. Whilst there 
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are isolated reports of invasive SCC and melanoma developing at sites treated by PDT, these 
are in patients with otherwise pre-malignant skin changes and any causal association with 
PDT is unproven.64 Although there is no convincing evidence of a carcinogenic risk of PDT, 
vigilance is recommended. Details and references of the adverse effects of topical PDT are 
included in a separate review.65 
 
 
10.0 RECOMMENDED AUDIT POINTS  
 
In the last 20 consecutive patients treated with PDT is there evidence of: 
 
1. Clearance rates of at least 75% of AK, SCC in situ and superficial BCC lesions 
(including daylight PDT for individual AK lesions or field areas): 
a. at 3 months after the last treatment  
b. at 12 months after the last treatment (SCC in situ and superficial BCC only) 
2. An effective pain management protocol for patients treated for individual AK, SCC 
in situ or BCC lesions who experience severe pain requiring interruption of 
treatment or local anaesthesia.  
3. Patient feedback on their:  
a. satisfaction with cosmetic outcome at 1 year (poor, moderate, good or 
excellent) 
b. satisfaction with PDT therapy in general (very satisfied, satisfied, dissatisfied, 
or very dissatisfied)  
c. preferred therapy, if they had received alternative therapies for the same/similar 
lesion previously. 
4. Initial clearance rates (3 months) of indications for which PDT use is not licenced. 
 
The audit recommendation of 20 cases per department is to reduce variation in the results, 
and allow benchmarking between different units. However, departments unable to achieve 
this recommendation may choose to audit all cases seen in the preceding 12 months. 
 
 
11.0 STAKEHOLDER INVOLVEMENT AND PEER REVIEW 
 
The draft document and supporting information was made available to the BAD membership, 
the British Photodermatology Group (BPG), British Dermatological Nursing Group (BDNG), 
Primary Care Dermatological Society (PCDS) and the Gorlin Syndrome Group for comments, 
which were actively considered by the GDG. Following further review, the finalized version 
was sent for peer-review by the Clinical Standards Unit of the BAD, made up of the Therapy 
& Guidelines Sub-committee (T&G), prior to submission for publication.  
 
 
12.0 LIMITATIONS OF THE GUIDELINE 
 
This document has been prepared on behalf of the BAD and is based on the best data 
available when the document was prepared. It is recognised that under certain conditions it 
may be necessary to deviate from the guidelines and that the results of future studies may 
require some of the recommendations herein to be changed. Additionally, it is acknowledged 
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that limited cost-effectiveness data in the context of UK healthcare setting may impact on the 
availability of a given therapy within the NHS, despite evidence of efficacy. Failure to adhere 
to these guidelines should not necessarily be considered negligent, nor should adherence to 
these recommendations constitute a defence against a claim of negligence. 
 
13.0 PLANS FOR GUIDELINE REVISION 
 
The proposed revision date for this set of recommendations is scheduled for 2023; where 
necessary, important interim changes will be updated on the BAD website. 
 
 
SUPPORTING INFORMATION 
Additional supporting information including the study selection PRISMA flow diagram, 
summary of findings with forest plots, GRADE evidence profiles indicating the quality of 
evidence, clinical evidence summary, summary of included studies, narrative findings for 
within-patient studies and non-comparative studies, LETR, list of excluded studies and search 
strategy may be found in the online version of this article. 
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